Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / MYO5A



This biomarker is also known as:
  • myosin VA (heavy chain 12, myoxin),
  • unconventional myosin-Va,
  • dilute myosin heavy chain, non-muscle,
  • Myosin-12,
  • Myoxin,
  • GS1,
  • MYH12,
  • Myosin heavy chain 12,
  • myosin-Va,
  • myosin VA (heavy polypeptide 12, myoxin),
  • MYR12,
  • myoxin,
  • MYO5,
  • myosin V,
  • Dilute myosin heavy chain, non-muscle,
  • myosin, heavy polypeptide kinase,
  • myosin-12,

View in BioMuta


The MYO5A gene is one of three myosin V heavy-chain genes, belonging to the myosin gene superfamily. The MYO5A protein functions as a processive actin-based motor that can move in large steps approximating the 36-nm pseudo-repeat of the actin filament. MYO5A is also involved in cytoplasmic vesicle transport and anchorage, spindle-pole alignment and mRNA translocation. Different isoforms, encoded by alternatively spliced transcript variants, have been reported.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

MYO5A was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.